Search academic texts

Information × Registration Number 0207U010139, 0105U000556 , R & D reports Title Development of treatment taktics in primary patients with refractory malignant lymphomas, taking into account the prognosis factors popup.stage_title Head Sivkovich S., Registration Date 27-12-2007 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 Object of study – patients with refractory forms of malignant limphomas (ML). Objective of study – to develop complex methods of the treatment of patients with refractory forms ML with taking into account predictive factors. Methods of study – morphological, imunohistochemical, clinical, statistical. As a result of our SRW we determine that administration of improving regimens of polychemotherapy (which except traditional drugs include Irinotecan, Paklitaxel, Oxaliplatin ) lead to compleate clinico-heamatological remission in 84% and partial remission in 14% in patients with smallcells and largecells, P53, Bcl-2, Pgp-positive Nonhodgkin’s lymphomas. It is appeared that 58% of the old age patients with Nonhodjkin’s lymphomas had compications of treatment. Using mitoxantron and idarubicin instead of doxyrubicin allow to avoid cardiotoxic effects. All of the old age patients which underwent regimens CNOP or CIOP reached clinico-heamatologic remission. It emerged that among patients with refractory formof Hodgkin’s disease there are more patients with poor prognosis. Hodgkin’s disease demands polychemotherapy regimens whith adding of Gemcitabin or Cisplatin (Gem-BEACOPP and Cis-BEACOPP) which lead to 78.3% of complete remission and 19.6% partial remission. Field of use – oncology. Product Description popup.authors popup.nrat_date 2020-04-02 Close